Jayson Rieger Buys 5,000 Shares of Verrica Pharmaceuticals (NASDAQ:VRCA) Stock

Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) CEO Jayson Rieger purchased 5,000 shares of the firm’s stock in a transaction that occurred on Monday, August 17th. The stock was purchased at an average price of $4.91 per share, with a total value of $24,550.00. Following the completion of the purchase, the chief executive officer directly owned 207,593 shares of the company’s stock, valued at approximately $1,019,281.63. This represents a 2.47% increase in their position. The purchase was disclosed in a filing with the SEC, which is available through the SEC website.

Verrica Pharmaceuticals Stock Up 6.6%

Shares of Verrica Pharmaceuticals stock opened at $4.99 on Thursday. The business has a 50-day moving average price of $5.64 and a 200 day moving average price of $5.90. Verrica Pharmaceuticals Inc. has a fifty-two week low of $3.28 and a fifty-two week high of $9.82. The firm has a market cap of $85.73 million, a P/E ratio of -2.99 and a beta of 1.49. The company has a quick ratio of 1.33, a current ratio of 1.45 and a debt-to-equity ratio of 0.18.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on VRCA shares. Weiss Ratings reissued a “sell (e+)” rating on shares of Verrica Pharmaceuticals in a research report on Wednesday, July 15th. HC Wainwright began coverage on shares of Verrica Pharmaceuticals in a research note on Tuesday, May 26th. They set a “buy” rating and a $12.00 target price for the company. Zacks Research raised shares of Verrica Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Monday, May 11th. Finally, Wall Street Zen downgraded shares of Verrica Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Saturday, August 15th. Two analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $14.50.

Institutional Trading of Verrica Pharmaceuticals

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Armistice Capital LLC boosted its position in Verrica Pharmaceuticals by 75.1% during the 4th quarter. Armistice Capital LLC now owns 1,118,925 shares of the company’s stock valued at $9,298,000 after purchasing an additional 479,732 shares during the period. Affinity Asset Advisors LLC bought a new stake in Verrica Pharmaceuticals in the fourth quarter valued at $5,878,000. Velan Capital Investment Management LP acquired a new position in shares of Verrica Pharmaceuticals during the fourth quarter valued at $3,919,000. Boothbay Fund Management LLC bought a new position in shares of Verrica Pharmaceuticals during the third quarter worth about $1,210,000. Finally, Kalehua Capital Management LLC acquired a new stake in shares of Verrica Pharmaceuticals in the 4th quarter worth about $1,959,000. 42.45% of the stock is currently owned by institutional investors and hedge funds.

About Verrica Pharmaceuticals

Verrica Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company focused on the development and commercialization of topical therapies for dermatological conditions. Its lead investigational product, VP-102, is a standardized formulation of cantharidin in a pre-measured applicator designed to treat molluscum contagiosum and common warts. Verrica’s approach emphasizes consistency of dosing and patient convenience, aiming to improve upon off‐label use of existing treatments.

Beyond VP-102, Verrica is advancing VP-103, a next‐generation topical candidate intended to optimize tolerability while maintaining efficacy against viral skin lesions.